A pair of studies presented at the American Epilepsy Society's (AES) 68th Annual Meeting will offer insights into the therapeutic effects of specialized diets in adults with epilepsy.
Three studies to be presented at the American Epilepsy Society's (AES) 68th Annual Meeting in December aim to improve communication around SUDEP by re-evaluating how death certificates are coded, and by promoting the accessibility and distribution of SUDEP-related information.
Three studies to be presented at the American Epilepsy Society's (AES) 68th Annual Meeting analyze potential factors that impair driving in people with epilepsy and in people who experience "seizure-like" non-epileptic events.
In a pair of studies to be featured at the American Epilepsy Society's (AES) 68th Annual Meeting, researchers describe innovative models for predicting seizure occurrence in critically ill children.
New findings from a phase 3 clinical trial to be unveiled at the American Epilepsy Society's (AES) 68th Annual Meeting suggest an additional therapeutic option may be coming down the pike.
Two studies to be presented at the American Epilepsy Society's (AES) 68th Annual Meeting explore the outcomes of brain surgery for children with severe epilepsy.
A pair of studies to be presented at the American Epilepsy Society’s (AES) 68th Annual Meeting provides innovative insights into the genetic underpinnings of childhood epilepsies.
A new study that will be featured at the American Epilepsy Society’s (AES) 68th Annual Meeting examines the reliability of optogenetics as a method of intervention of temporal lobe seizures, and the role the cerebellum may play in hippocampal function and seizure reduction.
An international competition using the wisdom of crowds has developed computer algorithms to detect, predict, and ultimately prevent epileptic seizures. A total of five-hundred and four teams competed in two challenges, one for Seizure Detection and a second for Seizure Prediction.
The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found. The study, led by a Yale Cancer Center investigator, is described in the Nov. 27 edition of the journal Nature.
Smokers who drink heavily have a tougher time quitting cigarettes than smokers who drink moderately or not at all. However, a multi-center study led by researchers in Yale Cancer Center and Yale School of Medicine found that modifying tobacco-oriented telephone counseling to help hazardous drinkers can help them quit smoking.
Expert can speak about Google’s plans to develop tiny magnetic particles to patrol the body for signs of cancer and other diseases, and a wearable device with a magnet to attract and count the particles as a monitoring tool. Edward Flynn, Ph.D. has years of experience developing a similar nanotech-based cancer detection system at Senior Scientific, a subsidiary of Manhattan Scientifics.
Greenwich Hospital and Orthopaedic and Neurosurgery Specialists Foundation (ONSF) conducted research to examine why a certain bacteria is so common in post-surgical shoulder infections.
New and more effective treatments for diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) are sorely needed. One of the today’s most promising approaches harnesses regenerative medicine, specifically cell therapy. Israel-based Macrocure Ltd.’s lead product, CureXcell™, harnesses living white blood cells, including macrophages, neutrophils and lymphocytes, that are crucial to initiating, promoting and completing the process of cellular regeneration and wound healing for both of these conditions.
While current epilepsy research may seem like it’s ripped from the pages of a science fiction novel, it’s real—and even pretty cool. Epilepsy provides researchers with unparalleled avenues to discover how the brain is structured and how it functions: a true ‘window on the brain.’ In recognition of Epilepsy Awareness Month the American Epilepsy Society (AES) is highlighting just a few of the groundbreaking scientific developments made within the last 10-50 years.
The U.S. Navy and Office of Naval Research are developing unmanned surface vehicle (USV) technology that allows USVs to act in tandem as an autonomous “swarm” of robot boats potentially providing enhanced security against enemy vessels. But the USV technology suffers from technical hurdles, including a lack of a stable platform required for proper communication among the boats. The Ghost—a high-speed attack craft designed by Juliet Marine Systems to protect vital waterways—offers a potential alternative, with stability on the water that the USV technology needs.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right